Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons (Q34620095)

3 August 2017

0 references

1 reference

title

Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons (English)

1 reference

3 August 2017

0 references

1 reference

extrapyramidal symptoms

1 reference

inferred from title

author

Christine Rummel-Kluge

1

object named as

Christine Rummel-Kluge

1 reference

3 August 2017

6

Werner Kissling

1 reference

3 August 2017

8

Stefan Leucht

1 reference

3 August 2017

Katja Komossa

2

1 reference

3 August 2017

Sandra Schwarz

3

1 reference

3 August 2017

Heike Hunger

4

1 reference

3 August 2017

Franziska Schmid

5

1 reference

3 August 2017

John M Davis

7

1 reference

3 August 2017

language of work or name

English

0 references

publication date

31 May 2010

1 reference

3 August 2017

Schizophrenia Bulletin

1 reference

3 August 2017

38

1 reference

3 August 2017

1

1 reference

3 August 2017

167-177

1 reference

Olanzapine versus other atypical antipsychotics for schizophrenia

3 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Zotepine versus other atypical antipsychotics for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Quetiapine versus other atypical antipsychotics for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Amisulpride versus other atypical antipsychotics for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Ziprasidone versus other atypical antipsychotics for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Aripiprazole versus other atypical antipsychotics for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Akathisia: an updated review focusing on second-generation antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Sertindole versus other atypical antipsychotics for schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

The 'atypicality' of antipsychotics: a concept re-examined and re-defined

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Classifying antipsychotic agents : need for new terminology

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Extrapyramidal side-effects of antipsychotics in a randomised trial

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Tardive dyskinesia and new antipsychotics

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

One-year incidence rates of tardive dyskinesia in children and adolescents treated with second-generation antipsychotics: a systematic review

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Novel antipsychotics, extrapyramidal side effects and tardive dyskinesia.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Determinants of medication compliance in schizophrenia: empirical and clinical findings

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Bias in meta-analysis detected by a simple, graphical test

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Meta-analysis in clinical trials

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Clozapine: guidelines for clinical management

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Clozapine: an atypical antipsychotic agent

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

Subjective response as a predictor of outcome in pharmacotherapy: the consumer has a point

7 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3245581

A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia

7 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ042

Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ042

Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FSCHBUL%2FSBQ042

Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology

21 January 2018

1 reference

12 December 2020

Evidence that early extrapyramidal symptoms predict later tardive dyskinesia: a prospective analysis of 10,000 patients in the European Schizophrenia Outpatient Health Outcomes (SOHO) study

1 reference

12 December 2020

Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia

1 reference

12 December 2020

Anticholinergic use in hospitalised schizophrenic patients in Belgium

1 reference

12 December 2020

Identifiers

DOI

10.1093/SCHBUL/SBQ042

1 reference

3 August 2017

1 reference

3 August 2017

1 reference